Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Cheyenne Pagan"'
Autor:
Susan M. Domchek, Robert L. Giuntoli, Diego Rodriguez, Stephanie Gaillard, Janos L. Tanyi, Nawar A. Latif, Cheyenne Pagan, Deborah K. Armstrong, Emma Dean, Robert A. Burger, Ie Ming Shih, Simon Smith, Ashley Haggerty, Lainie P. Martin, Mark A. Morgan, Stephanie L. Wethington, Ronny Drapkin, Payal D. Shah, Wei-Ting Hwang, Drew A. Torigian, Fiona Simpkins, Haley Zarrin
Publikováno v:
Gynecol Oncol
OBJECTIVE: Platinum-resistant, high-grade serous ovarian cancer (HGSOC) has limited treatment options. Preclinical data suggest that poly(ADP-ribose) polymerase inhibitors (PARPi) and ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c6882ea192defd2f25728f2fbfdafac
https://pubmed.ncbi.nlm.nih.gov/34620496
https://pubmed.ncbi.nlm.nih.gov/34620496
Autor:
Ie Ming Shih, Susan M. Domchek, Cheyenne Pagan, Diego Rodriguez, Mark A. Morgan, Lainie P. Martin, Drew A. Torigian, Emma Dean, Simon Smith, Stephanie Gaillard, Ronny Drapkin, Janos L. Tanyi, Fiona Simpkins, Nawar A. Latif, Deborah K. Armstrong, Stephanie L. Wethington, Payal D. Shah
Publikováno v:
Journal of Clinical Oncology. 39:5516-5516
5516 Background: Following multiple blockbuster studies demonstrating long-term progression free and overall survival benefits with poly(ADP-ribose)polymerase inhibitors (PARPi), they have become an integral component of high grade serous ovarian can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2b0b1aacd8f69badfec7d68f822f4e9
https://doi.org/10.1200/jco.2021.39.15_suppl.5516
https://doi.org/10.1200/jco.2021.39.15_suppl.5516